| GlaxoSmithKline AG - Fluarix Tetra 15 µg / 0.5 ml, Injektionssuspension | | 62961 | | 11 | | Fluarix Tetra 15 µg / 0.5 ml | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 10.07.2024 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Thailand/8/2022 (H3N2)-like: reassortant virus IVR-237 derived from A/Thailand/8/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: B/Phuket/3073/2013 wild type (Yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. | | Packungsbestandteile | | | | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 033 | | 9.58 | 26.85 | B | SL | Nein | | 034 | 10 | PA | PA | B | | Nein |
|
|
